Open access
Open access
Powered by Google Translator Translator

Oncology (all articles)

M-A | Margin status and survival outcomes after breast cancer conservation surgery.

23 Sep, 2022 | 13:09h | UTC

Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis – The BMJ

Commentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ

News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom

 


Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.

23 Sep, 2022 | 13:07h | UTC

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations – The BMJ

 

Commentary on Twitter

 


The current state of the art and future trends in RAS-targeted cancer therapies.

22 Sep, 2022 | 13:01h | UTC

The current state of the art and future trends in RAS-targeted cancer therapies – Nature Reviews Clinical Oncology

 

Commentary on Twitter

 


ASCO Guideline | Integrative medicine for pain management in oncology.

21 Sep, 2022 | 13:22h | UTC

Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline – Journal of Clinical Oncology

Commentary: New SIO-ASCO practice guideline addresses the use of integrative therapies for cancer pain management – News Medical

 


Single-arm Phase 1b/2 study | Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial cancer.

21 Sep, 2022 | 13:10h | UTC

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer – Journal of Clinical Oncology

Commentary: High ORR Associated With Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Cancer – Cancer Network

 


M-A of randomized trials | Prophylactic central neck lymph node dissection in low-risk thyroid carcinoma patients does not decrease the incidence of locoregional recurrence.

21 Sep, 2022 | 13:07h | UTC

Prophylactic Central Neck Lymph Node Dissection in Low-risk Thyroid Carcinoma Patients Does Not Decrease the Incidence of Locoregional Recurrence: A Meta-analysis of Randomized Trials – Annals of Surgery (link to abstract – $ for full-text)

 


Preliminary results of a RCT | Once-only colonoscopy vs. two rounds of fecal immunochemical testing 2 years apart for colorectal cancer screening.

20 Sep, 2022 | 13:29h | UTC

Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentary: Two Rounds of FIT vs Single Colonoscopy as a One-time CRC Screening – Medscape (free registration required)

 


M-A of randomized trials | Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer.

20 Sep, 2022 | 13:23h | UTC

Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials – ESMO Open

Related:

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial – JAMA Surgery

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer – New England Journal of Medicine

 


Single-arm phase 1/2 study | Tumor-agnostic efficacy and safety of Selpercatinib in patients with RET fusion-positive solid tumors other than lung or thyroid tumors.

20 Sep, 2022 | 13:18h | UTC

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial – The Lancet Oncology

Invited Commentary: Tissue-agnostic RET inhibition: can you trust your target? – The Lancet Oncology

News Release: RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population – University of Texas M. D. Anderson Cancer Center

 

Commentary from the author on Twitter (thread – click for more)

 


Systematic Review | Debulking hysterectomy followed by chemoradiotherapy vs. chemoradiotherapy alone for women with locally advanced cancer of the cervix – not enough evidence to guide recommendations.

19 Sep, 2022 | 12:39h | UTC

Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer – Cochrane Library

Summary: Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO (2019) stage IB3/II cervical cancer – Cochrane Library

 


Phase 2 RCT | Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.

19 Sep, 2022 | 12:32h | UTC

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial – The Lancet (free registration required for full-text)

Commentary: Dual checkpoint inhibitor blockade shows promise as first-line and salvage therapy for Merkel cell carcinoma patients – H. Lee Moffitt Cancer Center & Research Institute

 


RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.

19 Sep, 2022 | 12:31h | UTC

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter (thread – click for more)

 


ASCO Rapid Recommendation | Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer.

19 Sep, 2022 | 12:31h | UTC

Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation – Journal of Clinical Oncology

 


RCT | Short-term outcomes of laparoscopy-assisted vs. open surgery for patients with low rectal cancer.

16 Sep, 2022 | 12:58h | UTC

Short-term Outcomes of Laparoscopy-Assisted vs Open Surgery for Patients With Low Rectal Cancer: The LASRE Randomized Clinical Trial – JAMA Oncology

 

Commentary on Twitter

 


Cohort Study | Long-term outcomes among men undergoing active surveillance for prostate cancer.

15 Sep, 2022 | 13:11h | UTC

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden – JAMA Network Open

Invited Commentary: Exploring the Long-term Outcomes of Active Surveillance Among Men With Prostate Cancer—Best for Whom? – JAMA Network Open

 


RCT | Robotic vs. laparoscopic surgery for middle and low rectal cancer.

15 Sep, 2022 | 13:09h | UTC

Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentaries:

Robotic Surgery Tops Laparoscopic Surgery for Middle and Low Rectal Cancer — Randomized trial shows fewer positive circumferential resection margins with robotic technique – MedPage Today (free registration required)

 

Commentaries on Twitter

 


RCT | Extended duration thromboprophylaxis (continued for 56 days postoperatively) is not beneficial after surgical resection of colorectal cancer.

14 Sep, 2022 | 13:22h | UTC

Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial – The BMJ

 


Phase 2 RCT | Sequencing of Ipilimumab plus Nivolumab and Encorafenib plus Binimetinib for untreated BRAF-mutated metastatic melanoma.

14 Sep, 2022 | 13:01h | UTC

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma – OncLive

 

Commentary on Twitter

 


RCT | Efficacy and safety of carboplatin with nab-paclitaxel vs. docetaxel in older patients with squamous non-small-cell lung cancer.

14 Sep, 2022 | 13:00h | UTC

Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial – The Lancet Health Longevity

 

Commentary on Twitter

 


RCT | Dexamethasone is not effective for the treatment of dyspnea in patients with cancer and increases the risk of adverse events.

13 Sep, 2022 | 13:22h | UTC

Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial – The Lancet Oncology (free for a limited period)

 

Commentary on Twitter

 


Phase 2 single-arm study | Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.

13 Sep, 2022 | 13:11h | UTC

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC – Cancer Network

 

Commentary on Twitter

 


RCT | Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma.

13 Sep, 2022 | 13:03h | UTC

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence

 


Systematic Review | Ultra‐radical (extensive) surgery vs. standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

13 Sep, 2022 | 12:56h | UTC

Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer – Cochrane Library

Summary: Ultra-radical (extensive) surgery versus standard surgery to remove tumours in women with advanced ovarian cancer – Cochrane Library

Related Study: Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer – New England Journal of Medicine

 


RCT | Rezvilutamide vs. Bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer.

11 Sep, 2022 | 22:52h | UTC

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial – The Lancet Oncology

Commentaries:

Treatment options for metastatic hormone-sensitive prostate cancer – The Lancet Oncology

Rezvilutamide benefits shown in metastatic hormone-sensitive prostate cancer – medwire News

 

Commentary on Twitter

 


AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.

11 Sep, 2022 | 22:50h | UTC

AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology

 


Stay Updated in Your Specialty

No spam, just news.